nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP2C8—Mometasone—atopic dermatitis	0.0588	0.109	CbGbCtD
Bortezomib—PTGS1—Diphenhydramine—atopic dermatitis	0.0585	0.109	CbGbCtD
Bortezomib—CYP2C8—Loratadine—atopic dermatitis	0.0338	0.0628	CbGbCtD
Bortezomib—CYP3A4—Pimecrolimus—atopic dermatitis	0.0315	0.0585	CbGbCtD
Bortezomib—CYP2C19—Loratadine—atopic dermatitis	0.0283	0.0527	CbGbCtD
Bortezomib—CYP2C19—Diphenhydramine—atopic dermatitis	0.0283	0.0527	CbGbCtD
Bortezomib—CYP1A2—Diphenhydramine—atopic dermatitis	0.0261	0.0486	CbGbCtD
Bortezomib—CYP2C9—Loratadine—atopic dermatitis	0.0236	0.0438	CbGbCtD
Bortezomib—CYP2C9—Diphenhydramine—atopic dermatitis	0.0236	0.0438	CbGbCtD
Bortezomib—CYP2D6—Loratadine—atopic dermatitis	0.0215	0.04	CbGbCtD
Bortezomib—CYP2D6—Diphenhydramine—atopic dermatitis	0.0215	0.04	CbGbCtD
Bortezomib—CYP1A1—Dexamethasone—atopic dermatitis	0.0202	0.0376	CbGbCtD
Bortezomib—CYP2C8—Hydrocortisone—atopic dermatitis	0.0188	0.0349	CbGbCtD
Bortezomib—CYP3A4—Tacrolimus—atopic dermatitis	0.0187	0.0348	CbGbCtD
Bortezomib—CYP2C19—Prednisone—atopic dermatitis	0.0157	0.0292	CbGbCtD
Bortezomib—CYP3A4—Loratadine—atopic dermatitis	0.0137	0.0255	CbGbCtD
Bortezomib—CYP3A4—Methylprednisolone—atopic dermatitis	0.0125	0.0233	CbGbCtD
Bortezomib—CYP2C8—Dexamethasone—atopic dermatitis	0.0117	0.0217	CbGbCtD
Bortezomib—CYP2C19—Dexamethasone—atopic dermatitis	0.0098	0.0182	CbGbCtD
Bortezomib—CYP3A4—Triamcinolone—atopic dermatitis	0.00949	0.0176	CbGbCtD
Bortezomib—CYP2C9—Dexamethasone—atopic dermatitis	0.00815	0.0151	CbGbCtD
Bortezomib—CYP3A4—Betamethasone—atopic dermatitis	0.00814	0.0151	CbGbCtD
Bortezomib—CYP3A4—Prednisolone—atopic dermatitis	0.00804	0.0149	CbGbCtD
Bortezomib—CYP3A4—Hydrocortisone—atopic dermatitis	0.00762	0.0142	CbGbCtD
Bortezomib—CYP3A4—Prednisone—atopic dermatitis	0.00759	0.0141	CbGbCtD
Bortezomib—CYP2D6—Dexamethasone—atopic dermatitis	0.00745	0.0139	CbGbCtD
Bortezomib—PSMB2—skin epidermis—atopic dermatitis	0.00703	0.199	CbGeAlD
Bortezomib—CYP3A4—Dexamethasone—atopic dermatitis	0.00474	0.00881	CbGbCtD
Bortezomib—CTSG—skin of body—atopic dermatitis	0.00407	0.116	CbGeAlD
Bortezomib—PSMA1—skin of body—atopic dermatitis	0.00391	0.111	CbGeAlD
Bortezomib—PSMD2—skin of body—atopic dermatitis	0.00291	0.0825	CbGeAlD
Bortezomib—PSMA1—head—atopic dermatitis	0.00255	0.0724	CbGeAlD
Bortezomib—PSMB1—skin of body—atopic dermatitis	0.00223	0.0633	CbGeAlD
Bortezomib—PSMB2—skin of body—atopic dermatitis	0.00218	0.0618	CbGeAlD
Bortezomib—CYP1A1—skin epidermis—atopic dermatitis	0.00207	0.0587	CbGeAlD
Bortezomib—PSMD2—head—atopic dermatitis	0.0019	0.0538	CbGeAlD
Bortezomib—PSMB1—head—atopic dermatitis	0.00146	0.0413	CbGeAlD
Bortezomib—PSMB2—head—atopic dermatitis	0.00142	0.0403	CbGeAlD
Bortezomib—SLC31A1—head—atopic dermatitis	0.00123	0.0349	CbGeAlD
Bortezomib—PSMB5—Everolimus—Tacrolimus—atopic dermatitis	0.000946	0.113	CbGdCrCtD
Bortezomib—PSMD1—Temsirolimus—Tacrolimus—atopic dermatitis	0.000946	0.113	CbGdCrCtD
Bortezomib—PSMB5—Everolimus—Pimecrolimus—atopic dermatitis	0.000946	0.113	CbGdCrCtD
Bortezomib—PSMD1—Temsirolimus—Pimecrolimus—atopic dermatitis	0.000946	0.113	CbGdCrCtD
Bortezomib—PSMB8—Tacrolimus—Pimecrolimus—atopic dermatitis	0.000763	0.0909	CbGdCrCtD
Bortezomib—CYP1A1—skin of body—atopic dermatitis	0.00064	0.0182	CbGeAlD
Bortezomib—PTGS1—skin of body—atopic dermatitis	0.000563	0.016	CbGeAlD
Bortezomib—CYP1A1—head—atopic dermatitis	0.000418	0.0119	CbGeAlD
Bortezomib—PTGS1—head—atopic dermatitis	0.000367	0.0104	CbGeAlD
Bortezomib—CYP2D6—head—atopic dermatitis	0.000302	0.00856	CbGeAlD
Bortezomib—PSMB8—Everolimus—Tacrolimus—atopic dermatitis	0.000219	0.0261	CbGdCrCtD
Bortezomib—PSMB8—Everolimus—Pimecrolimus—atopic dermatitis	0.000219	0.0261	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Fluocinonide—atopic dermatitis	0.00013	0.0156	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Fluocinolone Acetonide—atopic dermatitis	0.000127	0.0151	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Desonide—atopic dermatitis	0.000117	0.014	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Mometasone—atopic dermatitis	0.000101	0.0121	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Fluocinonide—atopic dermatitis	9.39e-05	0.0112	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Fluocinolone Acetonide—atopic dermatitis	9.13e-05	0.0109	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Desonide—atopic dermatitis	8.93e-05	0.0107	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Desonide—atopic dermatitis	8.26e-05	0.00984	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Desonide—atopic dermatitis	8.26e-05	0.00984	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Mometasone—atopic dermatitis	7.28e-05	0.00868	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Fluocinonide—atopic dermatitis	7.15e-05	0.00853	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Fluocinolone Acetonide—atopic dermatitis	6.95e-05	0.00829	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Fluocinonide—atopic dermatitis	6.61e-05	0.00788	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Fluocinonide—atopic dermatitis	6.61e-05	0.00788	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Fluocinolone Acetonide—atopic dermatitis	6.43e-05	0.00766	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Fluocinolone Acetonide—atopic dermatitis	6.43e-05	0.00766	CbGdCrCtD
Bortezomib—PSMB8—Medrysone—Hydrocortisone—atopic dermatitis	6.37e-05	0.00759	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Methylprednisolone—atopic dermatitis	6.04e-05	0.0072	CbGdCrCtD
Bortezomib—PSMB8—Medrysone—Methylprednisolone—atopic dermatitis	6.01e-05	0.00716	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Betamethasone—atopic dermatitis	5.95e-05	0.00709	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Dexamethasone—atopic dermatitis	5.95e-05	0.00709	CbGdCrCtD
Bortezomib—Convulsion—Triamcinolone—atopic dermatitis	5.86e-05	0.000191	CcSEcCtD
Bortezomib—Tachycardia—Prednisolone—atopic dermatitis	5.86e-05	0.000191	CcSEcCtD
Bortezomib—Convulsion—Methylprednisolone—atopic dermatitis	5.85e-05	0.000191	CcSEcCtD
Bortezomib—Hypertension—Triamcinolone—atopic dermatitis	5.84e-05	0.000191	CcSEcCtD
Bortezomib—Hypertension—Methylprednisolone—atopic dermatitis	5.83e-05	0.00019	CcSEcCtD
Bortezomib—Infection—Hydrocortisone—atopic dermatitis	5.82e-05	0.00019	CcSEcCtD
Bortezomib—PSMD2—Fluticasone Propionate—Triamcinolone—atopic dermatitis	5.81e-05	0.00693	CbGdCrCtD
Bortezomib—Hyperhidrosis—Prednisolone—atopic dermatitis	5.8e-05	0.00019	CcSEcCtD
Bortezomib—Shock—Hydrocortisone—atopic dermatitis	5.77e-05	0.000188	CcSEcCtD
Bortezomib—Myalgia—Triamcinolone—atopic dermatitis	5.76e-05	0.000188	CcSEcCtD
Bortezomib—Nervous system disorder—Hydrocortisone—atopic dermatitis	5.75e-05	0.000188	CcSEcCtD
Bortezomib—Arthralgia—Methylprednisolone—atopic dermatitis	5.75e-05	0.000188	CcSEcCtD
Bortezomib—Myalgia—Methylprednisolone—atopic dermatitis	5.75e-05	0.000188	CcSEcCtD
Bortezomib—Eye disorder—Prednisone—atopic dermatitis	5.74e-05	0.000187	CcSEcCtD
Bortezomib—Anxiety—Methylprednisolone—atopic dermatitis	5.73e-05	0.000187	CcSEcCtD
Bortezomib—Tachycardia—Hydrocortisone—atopic dermatitis	5.72e-05	0.000187	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	5.71e-05	0.000186	CcSEcCtD
Bortezomib—Flushing—Prednisone—atopic dermatitis	5.7e-05	0.000186	CcSEcCtD
Bortezomib—Skin disorder—Hydrocortisone—atopic dermatitis	5.69e-05	0.000186	CcSEcCtD
Bortezomib—Ill-defined disorder—Dexamethasone—atopic dermatitis	5.69e-05	0.000186	CcSEcCtD
Bortezomib—Ill-defined disorder—Betamethasone—atopic dermatitis	5.69e-05	0.000186	CcSEcCtD
Bortezomib—Discomfort—Triamcinolone—atopic dermatitis	5.69e-05	0.000186	CcSEcCtD
Bortezomib—Discomfort—Methylprednisolone—atopic dermatitis	5.68e-05	0.000185	CcSEcCtD
Bortezomib—Hyperhidrosis—Hydrocortisone—atopic dermatitis	5.67e-05	0.000185	CcSEcCtD
Bortezomib—Angioedema—Dexamethasone—atopic dermatitis	5.61e-05	0.000183	CcSEcCtD
Bortezomib—Angioedema—Betamethasone—atopic dermatitis	5.61e-05	0.000183	CcSEcCtD
Bortezomib—Anorexia—Hydrocortisone—atopic dermatitis	5.59e-05	0.000183	CcSEcCtD
Bortezomib—Nausea—Tacrolimus—atopic dermatitis	5.58e-05	0.000182	CcSEcCtD
Bortezomib—Angiopathy—Prednisone—atopic dermatitis	5.57e-05	0.000182	CcSEcCtD
Bortezomib—Confusional state—Methylprednisolone—atopic dermatitis	5.55e-05	0.000181	CcSEcCtD
Bortezomib—PSMB8—Diflorasone—Mometasone—atopic dermatitis	5.55e-05	0.00661	CbGdCrCtD
Bortezomib—Immune system disorder—Prednisone—atopic dermatitis	5.55e-05	0.000181	CcSEcCtD
Bortezomib—Malaise—Betamethasone—atopic dermatitis	5.53e-05	0.000181	CcSEcCtD
Bortezomib—Malaise—Dexamethasone—atopic dermatitis	5.53e-05	0.000181	CcSEcCtD
Bortezomib—Oedema—Triamcinolone—atopic dermatitis	5.52e-05	0.00018	CcSEcCtD
Bortezomib—Anaphylactic shock—Triamcinolone—atopic dermatitis	5.52e-05	0.00018	CcSEcCtD
Bortezomib—Vertigo—Dexamethasone—atopic dermatitis	5.51e-05	0.00018	CcSEcCtD
Bortezomib—Vertigo—Betamethasone—atopic dermatitis	5.51e-05	0.00018	CcSEcCtD
Bortezomib—Anaphylactic shock—Methylprednisolone—atopic dermatitis	5.51e-05	0.00018	CcSEcCtD
Bortezomib—Syncope—Betamethasone—atopic dermatitis	5.5e-05	0.00018	CcSEcCtD
Bortezomib—Syncope—Dexamethasone—atopic dermatitis	5.5e-05	0.00018	CcSEcCtD
Bortezomib—Arrhythmia—Prednisone—atopic dermatitis	5.49e-05	0.000179	CcSEcCtD
Bortezomib—Infection—Triamcinolone—atopic dermatitis	5.48e-05	0.000179	CcSEcCtD
Bortezomib—Hypotension—Hydrocortisone—atopic dermatitis	5.48e-05	0.000179	CcSEcCtD
Bortezomib—Infection—Methylprednisolone—atopic dermatitis	5.47e-05	0.000179	CcSEcCtD
Bortezomib—Shock—Triamcinolone—atopic dermatitis	5.43e-05	0.000177	CcSEcCtD
Bortezomib—Insomnia—Prednisolone—atopic dermatitis	5.43e-05	0.000177	CcSEcCtD
Bortezomib—Shock—Methylprednisolone—atopic dermatitis	5.42e-05	0.000177	CcSEcCtD
Bortezomib—Nervous system disorder—Methylprednisolone—atopic dermatitis	5.4e-05	0.000176	CcSEcCtD
Bortezomib—Loss of consciousness—Dexamethasone—atopic dermatitis	5.39e-05	0.000176	CcSEcCtD
Bortezomib—Loss of consciousness—Betamethasone—atopic dermatitis	5.39e-05	0.000176	CcSEcCtD
Bortezomib—Paraesthesia—Prednisolone—atopic dermatitis	5.39e-05	0.000176	CcSEcCtD
Bortezomib—Tachycardia—Triamcinolone—atopic dermatitis	5.39e-05	0.000176	CcSEcCtD
Bortezomib—Mental disorder—Prednisone—atopic dermatitis	5.38e-05	0.000176	CcSEcCtD
Bortezomib—Tachycardia—Methylprednisolone—atopic dermatitis	5.38e-05	0.000176	CcSEcCtD
Bortezomib—PSMB8—Medrysone—Prednisolone—atopic dermatitis	5.35e-05	0.00638	CbGdCrCtD
Bortezomib—Skin disorder—Methylprednisolone—atopic dermatitis	5.35e-05	0.000175	CcSEcCtD
Bortezomib—Malnutrition—Prednisone—atopic dermatitis	5.35e-05	0.000175	CcSEcCtD
Bortezomib—Erythema—Prednisone—atopic dermatitis	5.35e-05	0.000175	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Hydrocortisone—atopic dermatitis	5.34e-05	0.000174	CcSEcCtD
Bortezomib—Hyperhidrosis—Triamcinolone—atopic dermatitis	5.34e-05	0.000174	CcSEcCtD
Bortezomib—Hyperhidrosis—Methylprednisolone—atopic dermatitis	5.33e-05	0.000174	CcSEcCtD
Bortezomib—Convulsion—Betamethasone—atopic dermatitis	5.32e-05	0.000174	CcSEcCtD
Bortezomib—Convulsion—Dexamethasone—atopic dermatitis	5.32e-05	0.000174	CcSEcCtD
Bortezomib—Insomnia—Hydrocortisone—atopic dermatitis	5.3e-05	0.000173	CcSEcCtD
Bortezomib—Hypertension—Betamethasone—atopic dermatitis	5.3e-05	0.000173	CcSEcCtD
Bortezomib—Hypertension—Dexamethasone—atopic dermatitis	5.3e-05	0.000173	CcSEcCtD
Bortezomib—Paraesthesia—Hydrocortisone—atopic dermatitis	5.26e-05	0.000172	CcSEcCtD
Bortezomib—Myalgia—Betamethasone—atopic dermatitis	5.23e-05	0.000171	CcSEcCtD
Bortezomib—Myalgia—Dexamethasone—atopic dermatitis	5.23e-05	0.000171	CcSEcCtD
Bortezomib—Anxiety—Dexamethasone—atopic dermatitis	5.21e-05	0.00017	CcSEcCtD
Bortezomib—Anxiety—Betamethasone—atopic dermatitis	5.21e-05	0.00017	CcSEcCtD
Bortezomib—Discomfort—Betamethasone—atopic dermatitis	5.16e-05	0.000169	CcSEcCtD
Bortezomib—Discomfort—Dexamethasone—atopic dermatitis	5.16e-05	0.000169	CcSEcCtD
Bortezomib—Dyspepsia—Hydrocortisone—atopic dermatitis	5.16e-05	0.000169	CcSEcCtD
Bortezomib—Hypotension—Methylprednisolone—atopic dermatitis	5.15e-05	0.000168	CcSEcCtD
Bortezomib—Pain—Prednisolone—atopic dermatitis	5.13e-05	0.000168	CcSEcCtD
Bortezomib—PSMD2—Betamethasone—Mometasone—atopic dermatitis	5.13e-05	0.00611	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Mometasone—atopic dermatitis	5.13e-05	0.00611	CbGdCrCtD
Bortezomib—PSMB8—Immune System—TLR2—atopic dermatitis	5.1e-05	0.000454	CbGpPWpGaD
Bortezomib—Decreased appetite—Hydrocortisone—atopic dermatitis	5.1e-05	0.000166	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	5.06e-05	0.000165	CcSEcCtD
Bortezomib—Fatigue—Hydrocortisone—atopic dermatitis	5.05e-05	0.000165	CcSEcCtD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	5.05e-05	0.00045	CbGpPWpGaD
Bortezomib—Vision blurred—Prednisone—atopic dermatitis	5.04e-05	0.000165	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Triamcinolone—atopic dermatitis	5.03e-05	0.000164	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methylprednisolone—atopic dermatitis	5.02e-05	0.000164	CcSEcCtD
Bortezomib—Pain—Hydrocortisone—atopic dermatitis	5.01e-05	0.000164	CcSEcCtD
Bortezomib—Anaphylactic shock—Betamethasone—atopic dermatitis	5.01e-05	0.000164	CcSEcCtD
Bortezomib—Anaphylactic shock—Dexamethasone—atopic dermatitis	5.01e-05	0.000164	CcSEcCtD
Bortezomib—Oedema—Betamethasone—atopic dermatitis	5.01e-05	0.000164	CcSEcCtD
Bortezomib—Oedema—Dexamethasone—atopic dermatitis	5.01e-05	0.000164	CcSEcCtD
Bortezomib—PSMB2—Adaptive Immune System—NFKBIA—atopic dermatitis	5.01e-05	0.000446	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—NFKBIA—atopic dermatitis	5.01e-05	0.000446	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—NFKBIA—atopic dermatitis	5.01e-05	0.000446	CbGpPWpGaD
Bortezomib—Insomnia—Triamcinolone—atopic dermatitis	4.99e-05	0.000163	CcSEcCtD
Bortezomib—Insomnia—Methylprednisolone—atopic dermatitis	4.98e-05	0.000163	CcSEcCtD
Bortezomib—Infection—Betamethasone—atopic dermatitis	4.98e-05	0.000163	CcSEcCtD
Bortezomib—Infection—Dexamethasone—atopic dermatitis	4.98e-05	0.000163	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—NPS—atopic dermatitis	4.97e-05	0.000443	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TAC1—atopic dermatitis	4.97e-05	0.000443	CbGpPWpGaD
Bortezomib—Ill-defined disorder—Prednisone—atopic dermatitis	4.96e-05	0.000162	CcSEcCtD
Bortezomib—Paraesthesia—Triamcinolone—atopic dermatitis	4.96e-05	0.000162	CcSEcCtD
Bortezomib—PSMD1—Signaling Pathways—NPS—atopic dermatitis	4.95e-05	0.000441	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TAC1—atopic dermatitis	4.95e-05	0.000441	CbGpPWpGaD
Bortezomib—Feeling abnormal—Prednisolone—atopic dermatitis	4.95e-05	0.000162	CcSEcCtD
Bortezomib—Paraesthesia—Methylprednisolone—atopic dermatitis	4.95e-05	0.000162	CcSEcCtD
Bortezomib—Anaemia—Prednisone—atopic dermatitis	4.94e-05	0.000161	CcSEcCtD
Bortezomib—PSMB8—Adaptive Immune System—NFKBIA—atopic dermatitis	4.94e-05	0.00044	CbGpPWpGaD
Bortezomib—Shock—Betamethasone—atopic dermatitis	4.93e-05	0.000161	CcSEcCtD
Bortezomib—Shock—Dexamethasone—atopic dermatitis	4.93e-05	0.000161	CcSEcCtD
Bortezomib—PSMD2—Signaling Pathways—TAC1—atopic dermatitis	4.93e-05	0.000438	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NPS—atopic dermatitis	4.93e-05	0.000438	CbGpPWpGaD
Bortezomib—Dyspnoea—Triamcinolone—atopic dermatitis	4.92e-05	0.000161	CcSEcCtD
Bortezomib—PTGS1—Selenium Micronutrient Network—IL6—atopic dermatitis	4.92e-05	0.000438	CbGpPWpGaD
Bortezomib—Nervous system disorder—Betamethasone—atopic dermatitis	4.91e-05	0.00016	CcSEcCtD
Bortezomib—Nervous system disorder—Dexamethasone—atopic dermatitis	4.91e-05	0.00016	CcSEcCtD
Bortezomib—Agitation—Prednisone—atopic dermatitis	4.91e-05	0.00016	CcSEcCtD
Bortezomib—Thrombocytopenia—Dexamethasone—atopic dermatitis	4.9e-05	0.00016	CcSEcCtD
Bortezomib—Thrombocytopenia—Betamethasone—atopic dermatitis	4.9e-05	0.00016	CcSEcCtD
Bortezomib—PSMA1—Adaptive Immune System—CD4—atopic dermatitis	4.9e-05	0.000436	CbGpPWpGaD
Bortezomib—Tachycardia—Dexamethasone—atopic dermatitis	4.89e-05	0.00016	CcSEcCtD
Bortezomib—Tachycardia—Betamethasone—atopic dermatitis	4.89e-05	0.00016	CcSEcCtD
Bortezomib—Angioedema—Prednisone—atopic dermatitis	4.88e-05	0.00016	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—CXCR3—atopic dermatitis	4.88e-05	0.000434	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—STAT6—atopic dermatitis	4.88e-05	0.000434	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—STAT6—atopic dermatitis	4.88e-05	0.000434	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—STAT6—atopic dermatitis	4.88e-05	0.000434	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—CD4—atopic dermatitis	4.87e-05	0.000434	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD79A—atopic dermatitis	4.86e-05	0.000433	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD79A—atopic dermatitis	4.86e-05	0.000433	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD79A—atopic dermatitis	4.86e-05	0.000433	CbGpPWpGaD
Bortezomib—Dyspepsia—Triamcinolone—atopic dermatitis	4.86e-05	0.000159	CcSEcCtD
Bortezomib—PSMD1—Signaling Pathways—CXCR3—atopic dermatitis	4.85e-05	0.000432	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—CD4—atopic dermatitis	4.85e-05	0.000432	CbGpPWpGaD
Bortezomib—Dyspepsia—Methylprednisolone—atopic dermatitis	4.85e-05	0.000158	CcSEcCtD
Bortezomib—Hyperhidrosis—Betamethasone—atopic dermatitis	4.84e-05	0.000158	CcSEcCtD
Bortezomib—Hyperhidrosis—Dexamethasone—atopic dermatitis	4.84e-05	0.000158	CcSEcCtD
Bortezomib—Feeling abnormal—Hydrocortisone—atopic dermatitis	4.83e-05	0.000158	CcSEcCtD
Bortezomib—PSMD2—Signaling Pathways—CXCR3—atopic dermatitis	4.83e-05	0.00043	CbGpPWpGaD
Bortezomib—Malaise—Prednisone—atopic dermatitis	4.82e-05	0.000157	CcSEcCtD
Bortezomib—PSMB8—Signaling Pathways—STAT6—atopic dermatitis	4.81e-05	0.000428	CbGpPWpGaD
Bortezomib—Vertigo—Prednisone—atopic dermatitis	4.8e-05	0.000157	CcSEcCtD
Bortezomib—Gastrointestinal pain—Hydrocortisone—atopic dermatitis	4.79e-05	0.000157	CcSEcCtD
Bortezomib—Syncope—Prednisone—atopic dermatitis	4.79e-05	0.000157	CcSEcCtD
Bortezomib—PSMB8—Immune System—CD79A—atopic dermatitis	4.79e-05	0.000427	CbGpPWpGaD
Bortezomib—PSMB8—Betamethasone—Desonide—atopic dermatitis	4.79e-05	0.00571	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Desonide—atopic dermatitis	4.79e-05	0.00571	CbGdCrCtD
Bortezomib—Anorexia—Dexamethasone—atopic dermatitis	4.77e-05	0.000156	CcSEcCtD
Bortezomib—Anorexia—Betamethasone—atopic dermatitis	4.77e-05	0.000156	CcSEcCtD
Bortezomib—Urticaria—Prednisolone—atopic dermatitis	4.77e-05	0.000156	CcSEcCtD
Bortezomib—Fatigue—Triamcinolone—atopic dermatitis	4.76e-05	0.000155	CcSEcCtD
Bortezomib—Fatigue—Methylprednisolone—atopic dermatitis	4.75e-05	0.000155	CcSEcCtD
Bortezomib—Pain—Triamcinolone—atopic dermatitis	4.72e-05	0.000154	CcSEcCtD
Bortezomib—Loss of consciousness—Prednisone—atopic dermatitis	4.7e-05	0.000153	CcSEcCtD
Bortezomib—Hypotension—Betamethasone—atopic dermatitis	4.68e-05	0.000153	CcSEcCtD
Bortezomib—Hypotension—Dexamethasone—atopic dermatitis	4.68e-05	0.000153	CcSEcCtD
Bortezomib—Urticaria—Hydrocortisone—atopic dermatitis	4.66e-05	0.000152	CcSEcCtD
Bortezomib—Body temperature increased—Hydrocortisone—atopic dermatitis	4.63e-05	0.000151	CcSEcCtD
Bortezomib—Abdominal pain—Hydrocortisone—atopic dermatitis	4.63e-05	0.000151	CcSEcCtD
Bortezomib—Convulsion—Prednisone—atopic dermatitis	4.63e-05	0.000151	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—IL5—atopic dermatitis	4.62e-05	0.000411	CbGpPWpGaD
Bortezomib—Hypertension—Prednisone—atopic dermatitis	4.61e-05	0.000151	CcSEcCtD
Bortezomib—PSMB8—Fluorometholone—Hydrocortisone—atopic dermatitis	4.61e-05	0.0055	CbGdCrCtD
Bortezomib—PSMD1—Signaling Pathways—IL5—atopic dermatitis	4.6e-05	0.00041	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—atopic dermatitis	4.6e-05	0.000409	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—atopic dermatitis	4.6e-05	0.000409	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL5—atopic dermatitis	4.58e-05	0.000408	CbGpPWpGaD
Bortezomib—Musculoskeletal discomfort—Betamethasone—atopic dermatitis	4.56e-05	0.000149	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Dexamethasone—atopic dermatitis	4.56e-05	0.000149	CcSEcCtD
Bortezomib—Myalgia—Prednisone—atopic dermatitis	4.55e-05	0.000149	CcSEcCtD
Bortezomib—Arthralgia—Prednisone—atopic dermatitis	4.55e-05	0.000149	CcSEcCtD
Bortezomib—Feeling abnormal—Triamcinolone—atopic dermatitis	4.55e-05	0.000149	CcSEcCtD
Bortezomib—Feeling abnormal—Methylprednisolone—atopic dermatitis	4.54e-05	0.000148	CcSEcCtD
Bortezomib—Anxiety—Prednisone—atopic dermatitis	4.53e-05	0.000148	CcSEcCtD
Bortezomib—Insomnia—Dexamethasone—atopic dermatitis	4.53e-05	0.000148	CcSEcCtD
Bortezomib—Insomnia—Betamethasone—atopic dermatitis	4.53e-05	0.000148	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	4.52e-05	0.000148	CcSEcCtD
Bortezomib—PSMA1—Gene Expression—PPARA—atopic dermatitis	4.51e-05	0.000401	CbGpPWpGaD
Bortezomib—Gastrointestinal pain—Methylprednisolone—atopic dermatitis	4.5e-05	0.000147	CcSEcCtD
Bortezomib—Paraesthesia—Betamethasone—atopic dermatitis	4.5e-05	0.000147	CcSEcCtD
Bortezomib—Paraesthesia—Dexamethasone—atopic dermatitis	4.5e-05	0.000147	CcSEcCtD
Bortezomib—Discomfort—Prednisone—atopic dermatitis	4.5e-05	0.000147	CcSEcCtD
Bortezomib—PSMD1—Gene Expression—PPARA—atopic dermatitis	4.49e-05	0.000399	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—PPARA—atopic dermatitis	4.47e-05	0.000397	CbGpPWpGaD
Bortezomib—Hypersensitivity—Prednisolone—atopic dermatitis	4.42e-05	0.000144	CcSEcCtD
Bortezomib—Dyspepsia—Dexamethasone—atopic dermatitis	4.41e-05	0.000144	CcSEcCtD
Bortezomib—Dyspepsia—Betamethasone—atopic dermatitis	4.41e-05	0.000144	CcSEcCtD
Bortezomib—Urticaria—Triamcinolone—atopic dermatitis	4.39e-05	0.000143	CcSEcCtD
Bortezomib—Urticaria—Methylprednisolone—atopic dermatitis	4.38e-05	0.000143	CcSEcCtD
Bortezomib—PSMA1—Disease—CCR5—atopic dermatitis	4.37e-05	0.000389	CbGpPWpGaD
Bortezomib—Body temperature increased—Triamcinolone—atopic dermatitis	4.36e-05	0.000143	CcSEcCtD
Bortezomib—Anaphylactic shock—Prednisone—atopic dermatitis	4.36e-05	0.000142	CcSEcCtD
Bortezomib—Oedema—Prednisone—atopic dermatitis	4.36e-05	0.000142	CcSEcCtD
Bortezomib—Abdominal pain—Methylprednisolone—atopic dermatitis	4.35e-05	0.000142	CcSEcCtD
Bortezomib—Decreased appetite—Dexamethasone—atopic dermatitis	4.35e-05	0.000142	CcSEcCtD
Bortezomib—Decreased appetite—Betamethasone—atopic dermatitis	4.35e-05	0.000142	CcSEcCtD
Bortezomib—PSMB8—Fluorometholone—Methylprednisolone—atopic dermatitis	4.35e-05	0.00519	CbGdCrCtD
Bortezomib—PSMD1—Disease—CCR5—atopic dermatitis	4.34e-05	0.000387	CbGpPWpGaD
Bortezomib—Infection—Prednisone—atopic dermatitis	4.33e-05	0.000142	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	4.32e-05	0.000141	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Betamethasone—atopic dermatitis	4.32e-05	0.000141	CcSEcCtD
Bortezomib—PSMD2—Disease—CCR5—atopic dermatitis	4.32e-05	0.000385	CbGpPWpGaD
Bortezomib—Hypersensitivity—Hydrocortisone—atopic dermatitis	4.32e-05	0.000141	CcSEcCtD
Bortezomib—Fatigue—Betamethasone—atopic dermatitis	4.32e-05	0.000141	CcSEcCtD
Bortezomib—Fatigue—Dexamethasone—atopic dermatitis	4.32e-05	0.000141	CcSEcCtD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	4.32e-05	0.000384	CbGpPWpGaD
Bortezomib—Shock—Prednisone—atopic dermatitis	4.29e-05	0.00014	CcSEcCtD
Bortezomib—Pain—Betamethasone—atopic dermatitis	4.28e-05	0.00014	CcSEcCtD
Bortezomib—Pain—Dexamethasone—atopic dermatitis	4.28e-05	0.00014	CcSEcCtD
Bortezomib—PSMB8—Fluorometholone—Dexamethasone—atopic dermatitis	4.28e-05	0.0051	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Betamethasone—atopic dermatitis	4.28e-05	0.0051	CbGdCrCtD
Bortezomib—PTGS1—Metabolism—GLB1—atopic dermatitis	4.28e-05	0.000381	CbGpPWpGaD
Bortezomib—Nervous system disorder—Prednisone—atopic dermatitis	4.28e-05	0.00014	CcSEcCtD
Bortezomib—Tachycardia—Prednisone—atopic dermatitis	4.26e-05	0.000139	CcSEcCtD
Bortezomib—Skin disorder—Prednisone—atopic dermatitis	4.24e-05	0.000138	CcSEcCtD
Bortezomib—PSMB5—Signaling Pathways—CCR3—atopic dermatitis	4.23e-05	0.000376	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCR3—atopic dermatitis	4.23e-05	0.000376	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCR3—atopic dermatitis	4.23e-05	0.000376	CbGpPWpGaD
Bortezomib—Hyperhidrosis—Prednisone—atopic dermatitis	4.22e-05	0.000138	CcSEcCtD
Bortezomib—Asthenia—Hydrocortisone—atopic dermatitis	4.21e-05	0.000137	CcSEcCtD
Bortezomib—PSMB8—Fluorometholone—Triamcinolone—atopic dermatitis	4.18e-05	0.00499	CbGdCrCtD
Bortezomib—PSMB8—Signaling Pathways—CCR3—atopic dermatitis	4.17e-05	0.000371	CbGpPWpGaD
Bortezomib—Anorexia—Prednisone—atopic dermatitis	4.16e-05	0.000136	CcSEcCtD
Bortezomib—Pruritus—Hydrocortisone—atopic dermatitis	4.15e-05	0.000135	CcSEcCtD
Bortezomib—Feeling abnormal—Betamethasone—atopic dermatitis	4.13e-05	0.000135	CcSEcCtD
Bortezomib—Feeling abnormal—Dexamethasone—atopic dermatitis	4.13e-05	0.000135	CcSEcCtD
Bortezomib—PTGS1—Metabolism—ADSL—atopic dermatitis	4.1e-05	0.000365	CbGpPWpGaD
Bortezomib—Gastrointestinal pain—Dexamethasone—atopic dermatitis	4.1e-05	0.000134	CcSEcCtD
Bortezomib—Gastrointestinal pain—Betamethasone—atopic dermatitis	4.1e-05	0.000134	CcSEcCtD
Bortezomib—Hypersensitivity—Triamcinolone—atopic dermatitis	4.07e-05	0.000133	CcSEcCtD
Bortezomib—Hypersensitivity—Methylprednisolone—atopic dermatitis	4.06e-05	0.000133	CcSEcCtD
Bortezomib—Diarrhoea—Hydrocortisone—atopic dermatitis	4.01e-05	0.000131	CcSEcCtD
Bortezomib—PSMA1—Immune System—NFKBIA—atopic dermatitis	4.01e-05	0.000357	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—NFKBIA—atopic dermatitis	3.99e-05	0.000355	CbGpPWpGaD
Bortezomib—Urticaria—Betamethasone—atopic dermatitis	3.98e-05	0.00013	CcSEcCtD
Bortezomib—Urticaria—Dexamethasone—atopic dermatitis	3.98e-05	0.00013	CcSEcCtD
Bortezomib—PSMB2—Immune System—IL18—atopic dermatitis	3.98e-05	0.000354	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL18—atopic dermatitis	3.98e-05	0.000354	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL18—atopic dermatitis	3.98e-05	0.000354	CbGpPWpGaD
Bortezomib—Musculoskeletal discomfort—Prednisone—atopic dermatitis	3.97e-05	0.00013	CcSEcCtD
Bortezomib—PSMD2—Immune System—NFKBIA—atopic dermatitis	3.97e-05	0.000353	CbGpPWpGaD
Bortezomib—PSMB8—Fluorometholone—Prednisone—atopic dermatitis	3.97e-05	0.00473	CbGdCrCtD
Bortezomib—Dizziness—Prednisolone—atopic dermatitis	3.97e-05	0.00013	CcSEcCtD
Bortezomib—Asthenia—Triamcinolone—atopic dermatitis	3.96e-05	0.000129	CcSEcCtD
Bortezomib—Abdominal pain—Betamethasone—atopic dermatitis	3.96e-05	0.000129	CcSEcCtD
Bortezomib—Abdominal pain—Dexamethasone—atopic dermatitis	3.96e-05	0.000129	CcSEcCtD
Bortezomib—Body temperature increased—Dexamethasone—atopic dermatitis	3.96e-05	0.000129	CcSEcCtD
Bortezomib—Body temperature increased—Betamethasone—atopic dermatitis	3.96e-05	0.000129	CcSEcCtD
Bortezomib—Asthenia—Methylprednisolone—atopic dermatitis	3.95e-05	0.000129	CcSEcCtD
Bortezomib—Insomnia—Prednisone—atopic dermatitis	3.95e-05	0.000129	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—CXCL10—atopic dermatitis	3.94e-05	0.000351	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CXCL10—atopic dermatitis	3.92e-05	0.000349	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL18—atopic dermatitis	3.92e-05	0.000349	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD8A—atopic dermatitis	3.92e-05	0.000349	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD8A—atopic dermatitis	3.92e-05	0.000349	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD8A—atopic dermatitis	3.92e-05	0.000349	CbGpPWpGaD
Bortezomib—Paraesthesia—Prednisone—atopic dermatitis	3.92e-05	0.000128	CcSEcCtD
Bortezomib—Pruritus—Triamcinolone—atopic dermatitis	3.91e-05	0.000128	CcSEcCtD
Bortezomib—PSMD2—Signaling Pathways—CXCL10—atopic dermatitis	3.9e-05	0.000348	CbGpPWpGaD
Bortezomib—Pruritus—Methylprednisolone—atopic dermatitis	3.9e-05	0.000127	CcSEcCtD
Bortezomib—Dizziness—Hydrocortisone—atopic dermatitis	3.88e-05	0.000127	CcSEcCtD
Bortezomib—PSMB8—Fluorometholone—Prednisolone—atopic dermatitis	3.88e-05	0.00462	CbGdCrCtD
Bortezomib—PSMB8—Immune System—CD8A—atopic dermatitis	3.86e-05	0.000344	CbGpPWpGaD
Bortezomib—Dyspepsia—Prednisone—atopic dermatitis	3.84e-05	0.000125	CcSEcCtD
Bortezomib—PSMB8—Betamethasone—Fluocinonide—atopic dermatitis	3.84e-05	0.00457	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Fluocinonide—atopic dermatitis	3.84e-05	0.00457	CbGdCrCtD
Bortezomib—Decreased appetite—Prednisone—atopic dermatitis	3.79e-05	0.000124	CcSEcCtD
Bortezomib—Rash—Prednisolone—atopic dermatitis	3.79e-05	0.000124	CcSEcCtD
Bortezomib—Dermatitis—Prednisolone—atopic dermatitis	3.78e-05	0.000124	CcSEcCtD
Bortezomib—Diarrhoea—Methylprednisolone—atopic dermatitis	3.77e-05	0.000123	CcSEcCtD
Bortezomib—PSMB2—Signaling Pathways—NPS—atopic dermatitis	3.77e-05	0.000335	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TAC1—atopic dermatitis	3.77e-05	0.000335	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TAC1—atopic dermatitis	3.77e-05	0.000335	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TAC1—atopic dermatitis	3.77e-05	0.000335	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NPS—atopic dermatitis	3.77e-05	0.000335	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NPS—atopic dermatitis	3.77e-05	0.000335	CbGpPWpGaD
Bortezomib—Fatigue—Prednisone—atopic dermatitis	3.76e-05	0.000123	CcSEcCtD
Bortezomib—Headache—Prednisolone—atopic dermatitis	3.76e-05	0.000123	CcSEcCtD
Bortezomib—Constipation—Prednisone—atopic dermatitis	3.73e-05	0.000122	CcSEcCtD
Bortezomib—PSMB8—Betamethasone—Fluocinolone Acetonide—atopic dermatitis	3.73e-05	0.00445	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Fluocinolone Acetonide—atopic dermatitis	3.73e-05	0.00445	CbGdCrCtD
Bortezomib—Vomiting—Hydrocortisone—atopic dermatitis	3.73e-05	0.000122	CcSEcCtD
Bortezomib—PSMB8—Signaling Pathways—TAC1—atopic dermatitis	3.72e-05	0.000331	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NPS—atopic dermatitis	3.72e-05	0.000331	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—CD4—atopic dermatitis	3.71e-05	0.00033	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—CD4—atopic dermatitis	3.71e-05	0.00033	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—CD4—atopic dermatitis	3.71e-05	0.00033	CbGpPWpGaD
Bortezomib—Rash—Hydrocortisone—atopic dermatitis	3.7e-05	0.000121	CcSEcCtD
Bortezomib—PSMB2—Signaling Pathways—CXCR3—atopic dermatitis	3.7e-05	0.000329	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CXCR3—atopic dermatitis	3.7e-05	0.000329	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CXCR3—atopic dermatitis	3.7e-05	0.000329	CbGpPWpGaD
Bortezomib—Dermatitis—Hydrocortisone—atopic dermatitis	3.69e-05	0.000121	CcSEcCtD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—IL6—atopic dermatitis	3.67e-05	0.000327	CbGpPWpGaD
Bortezomib—Headache—Hydrocortisone—atopic dermatitis	3.67e-05	0.00012	CcSEcCtD
Bortezomib—PSMB8—Adaptive Immune System—CD4—atopic dermatitis	3.66e-05	0.000326	CbGpPWpGaD
Bortezomib—Dizziness—Triamcinolone—atopic dermatitis	3.65e-05	0.000119	CcSEcCtD
Bortezomib—PSMB8—Signaling Pathways—CXCR3—atopic dermatitis	3.64e-05	0.000324	CbGpPWpGaD
Bortezomib—Dizziness—Methylprednisolone—atopic dermatitis	3.64e-05	0.000119	CcSEcCtD
Bortezomib—PSMA1—Immune System—CASP8—atopic dermatitis	3.62e-05	0.000322	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CASP8—atopic dermatitis	3.6e-05	0.00032	CbGpPWpGaD
Bortezomib—Feeling abnormal—Prednisone—atopic dermatitis	3.59e-05	0.000117	CcSEcCtD
Bortezomib—Asthenia—Dexamethasone—atopic dermatitis	3.59e-05	0.000117	CcSEcCtD
Bortezomib—Asthenia—Betamethasone—atopic dermatitis	3.59e-05	0.000117	CcSEcCtD
Bortezomib—PSMD2—Immune System—CASP8—atopic dermatitis	3.58e-05	0.000319	CbGpPWpGaD
Bortezomib—Gastrointestinal pain—Prednisone—atopic dermatitis	3.57e-05	0.000117	CcSEcCtD
Bortezomib—Nausea—Prednisolone—atopic dermatitis	3.57e-05	0.000116	CcSEcCtD
Bortezomib—PSMB8—Testosterone Propionate—Hydrocortisone—atopic dermatitis	3.55e-05	0.00423	CbGdCrCtD
Bortezomib—Pruritus—Betamethasone—atopic dermatitis	3.54e-05	0.000116	CcSEcCtD
Bortezomib—Pruritus—Dexamethasone—atopic dermatitis	3.54e-05	0.000116	CcSEcCtD
Bortezomib—Vomiting—Triamcinolone—atopic dermatitis	3.51e-05	0.000115	CcSEcCtD
Bortezomib—PSMA1—Metabolism—PPARA—atopic dermatitis	3.51e-05	0.000312	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL5—atopic dermatitis	3.5e-05	0.000312	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL5—atopic dermatitis	3.5e-05	0.000312	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL5—atopic dermatitis	3.5e-05	0.000312	CbGpPWpGaD
Bortezomib—Vomiting—Methylprednisolone—atopic dermatitis	3.5e-05	0.000114	CcSEcCtD
Bortezomib—PSMD1—Metabolism—PPARA—atopic dermatitis	3.49e-05	0.00031	CbGpPWpGaD
Bortezomib—Nausea—Hydrocortisone—atopic dermatitis	3.48e-05	0.000114	CcSEcCtD
Bortezomib—Rash—Triamcinolone—atopic dermatitis	3.48e-05	0.000114	CcSEcCtD
Bortezomib—Dermatitis—Triamcinolone—atopic dermatitis	3.48e-05	0.000114	CcSEcCtD
Bortezomib—Rash—Methylprednisolone—atopic dermatitis	3.47e-05	0.000113	CcSEcCtD
Bortezomib—PSMD2—Metabolism—PPARA—atopic dermatitis	3.47e-05	0.000309	CbGpPWpGaD
Bortezomib—Dermatitis—Methylprednisolone—atopic dermatitis	3.47e-05	0.000113	CcSEcCtD
Bortezomib—Urticaria—Prednisone—atopic dermatitis	3.47e-05	0.000113	CcSEcCtD
Bortezomib—Headache—Triamcinolone—atopic dermatitis	3.46e-05	0.000113	CcSEcCtD
Bortezomib—PSMB8—Signaling Pathways—IL5—atopic dermatitis	3.45e-05	0.000307	CbGpPWpGaD
Bortezomib—Headache—Methylprednisolone—atopic dermatitis	3.45e-05	0.000113	CcSEcCtD
Bortezomib—Abdominal pain—Prednisone—atopic dermatitis	3.45e-05	0.000113	CcSEcCtD
Bortezomib—Body temperature increased—Prednisone—atopic dermatitis	3.45e-05	0.000113	CcSEcCtD
Bortezomib—Diarrhoea—Betamethasone—atopic dermatitis	3.43e-05	0.000112	CcSEcCtD
Bortezomib—Diarrhoea—Dexamethasone—atopic dermatitis	3.43e-05	0.000112	CcSEcCtD
Bortezomib—PSMB1—Gene Expression—PPARA—atopic dermatitis	3.42e-05	0.000304	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—PPARA—atopic dermatitis	3.42e-05	0.000304	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—PPARA—atopic dermatitis	3.42e-05	0.000304	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CCL5—atopic dermatitis	3.39e-05	0.000302	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CCL5—atopic dermatitis	3.38e-05	0.000301	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—PPARA—atopic dermatitis	3.37e-05	0.0003	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CCL5—atopic dermatitis	3.36e-05	0.000299	CbGpPWpGaD
Bortezomib—PSMB8—Diflorasone—Methylprednisolone—atopic dermatitis	3.31e-05	0.00395	CbGdCrCtD
Bortezomib—Dizziness—Dexamethasone—atopic dermatitis	3.31e-05	0.000108	CcSEcCtD
Bortezomib—Dizziness—Betamethasone—atopic dermatitis	3.31e-05	0.000108	CcSEcCtD
Bortezomib—PSMB2—Disease—CCR5—atopic dermatitis	3.31e-05	0.000294	CbGpPWpGaD
Bortezomib—PSMB1—Disease—CCR5—atopic dermatitis	3.31e-05	0.000294	CbGpPWpGaD
Bortezomib—PSMB5—Disease—CCR5—atopic dermatitis	3.31e-05	0.000294	CbGpPWpGaD
Bortezomib—Nausea—Triamcinolone—atopic dermatitis	3.28e-05	0.000107	CcSEcCtD
Bortezomib—Nausea—Methylprednisolone—atopic dermatitis	3.27e-05	0.000107	CcSEcCtD
Bortezomib—PSMB8—Disease—CCR5—atopic dermatitis	3.26e-05	0.00029	CbGpPWpGaD
Bortezomib—PSMB8—Diflorasone—Betamethasone—atopic dermatitis	3.26e-05	0.00389	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Dexamethasone—atopic dermatitis	3.26e-05	0.00389	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Hydrocortisone—atopic dermatitis	3.25e-05	0.00387	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Hydrocortisone—atopic dermatitis	3.25e-05	0.00387	CbGdCrCtD
Bortezomib—Hypersensitivity—Prednisone—atopic dermatitis	3.21e-05	0.000105	CcSEcCtD
Bortezomib—PSMB8—Diflorasone—Triamcinolone—atopic dermatitis	3.19e-05	0.0038	CbGdCrCtD
Bortezomib—Vomiting—Betamethasone—atopic dermatitis	3.18e-05	0.000104	CcSEcCtD
Bortezomib—Vomiting—Dexamethasone—atopic dermatitis	3.18e-05	0.000104	CcSEcCtD
Bortezomib—Rash—Betamethasone—atopic dermatitis	3.16e-05	0.000103	CcSEcCtD
Bortezomib—Rash—Dexamethasone—atopic dermatitis	3.16e-05	0.000103	CcSEcCtD
Bortezomib—Dermatitis—Dexamethasone—atopic dermatitis	3.16e-05	0.000103	CcSEcCtD
Bortezomib—Dermatitis—Betamethasone—atopic dermatitis	3.16e-05	0.000103	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—NGF—atopic dermatitis	3.14e-05	0.00028	CbGpPWpGaD
Bortezomib—Headache—Betamethasone—atopic dermatitis	3.14e-05	0.000102	CcSEcCtD
Bortezomib—Headache—Dexamethasone—atopic dermatitis	3.14e-05	0.000102	CcSEcCtD
Bortezomib—Asthenia—Prednisone—atopic dermatitis	3.13e-05	0.000102	CcSEcCtD
Bortezomib—PSMD1—Signaling Pathways—NGF—atopic dermatitis	3.13e-05	0.000278	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	3.12e-05	0.000278	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NGF—atopic dermatitis	3.11e-05	0.000277	CbGpPWpGaD
Bortezomib—Pruritus—Prednisone—atopic dermatitis	3.09e-05	0.000101	CcSEcCtD
Bortezomib—PSMA1—Immune System—IFNG—atopic dermatitis	3.07e-05	0.000274	CbGpPWpGaD
Bortezomib—PSMD2—Dexamethasone—Methylprednisolone—atopic dermatitis	3.06e-05	0.00365	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Methylprednisolone—atopic dermatitis	3.06e-05	0.00365	CbGdCrCtD
Bortezomib—PSMD1—Immune System—IFNG—atopic dermatitis	3.06e-05	0.000272	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CCR5—atopic dermatitis	3.06e-05	0.000272	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IFNG—atopic dermatitis	3.05e-05	0.000271	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CCR5—atopic dermatitis	3.04e-05	0.000271	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—NFKBIA—atopic dermatitis	3.04e-05	0.00027	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—NFKBIA—atopic dermatitis	3.04e-05	0.00027	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—NFKBIA—atopic dermatitis	3.04e-05	0.00027	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CCR5—atopic dermatitis	3.03e-05	0.00027	CbGpPWpGaD
Bortezomib—PSMB8—Diflorasone—Prednisone—atopic dermatitis	3.02e-05	0.00361	CbGdCrCtD
Bortezomib—CYP1A1—Metabolism—GLB1—atopic dermatitis	3.01e-05	0.000268	CbGpPWpGaD
Bortezomib—PSMD2—Betamethasone—Dexamethasone—atopic dermatitis	3.01e-05	0.00359	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Betamethasone—atopic dermatitis	3.01e-05	0.00359	CbGdCrCtD
Bortezomib—PSMB8—Immune System—NFKBIA—atopic dermatitis	3e-05	0.000267	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CXCL10—atopic dermatitis	2.99e-05	0.000266	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CXCL10—atopic dermatitis	2.99e-05	0.000266	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CXCL10—atopic dermatitis	2.99e-05	0.000266	CbGpPWpGaD
Bortezomib—Diarrhoea—Prednisone—atopic dermatitis	2.98e-05	9.75e-05	CcSEcCtD
Bortezomib—Nausea—Dexamethasone—atopic dermatitis	2.98e-05	9.72e-05	CcSEcCtD
Bortezomib—Nausea—Betamethasone—atopic dermatitis	2.98e-05	9.72e-05	CcSEcCtD
Bortezomib—PSMB8—Dexamethasone—Mometasone—atopic dermatitis	2.97e-05	0.00355	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Mometasone—atopic dermatitis	2.97e-05	0.00355	CbGdCrCtD
Bortezomib—PSMA1—Immune System—CD4—atopic dermatitis	2.97e-05	0.000264	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CD4—atopic dermatitis	2.96e-05	0.000263	CbGpPWpGaD
Bortezomib—PSMB8—Diflorasone—Prednisolone—atopic dermatitis	2.95e-05	0.00352	CbGdCrCtD
Bortezomib—PSMB8—Signaling Pathways—CXCL10—atopic dermatitis	2.95e-05	0.000262	CbGpPWpGaD
Bortezomib—PSMD2—Dexamethasone—Triamcinolone—atopic dermatitis	2.94e-05	0.00351	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Triamcinolone—atopic dermatitis	2.94e-05	0.00351	CbGdCrCtD
Bortezomib—PSMD2—Immune System—CD4—atopic dermatitis	2.94e-05	0.000262	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ADSL—atopic dermatitis	2.89e-05	0.000257	CbGpPWpGaD
Bortezomib—Dizziness—Prednisone—atopic dermatitis	2.88e-05	9.42e-05	CcSEcCtD
Bortezomib—PSMD2—Betamethasone—Prednisone—atopic dermatitis	2.79e-05	0.00333	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Prednisone—atopic dermatitis	2.79e-05	0.00333	CbGdCrCtD
Bortezomib—Vomiting—Prednisone—atopic dermatitis	2.77e-05	9.06e-05	CcSEcCtD
Bortezomib—CYP2C8—Metabolism—GLB1—atopic dermatitis	2.76e-05	0.000246	CbGpPWpGaD
Bortezomib—Rash—Prednisone—atopic dermatitis	2.75e-05	8.98e-05	CcSEcCtD
Bortezomib—Dermatitis—Prednisone—atopic dermatitis	2.75e-05	8.98e-05	CcSEcCtD
Bortezomib—PSMA1—Immune System—IL1B—atopic dermatitis	2.74e-05	0.000244	CbGpPWpGaD
Bortezomib—PSMA1—Disease—CD4—atopic dermatitis	2.74e-05	0.000244	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CASP8—atopic dermatitis	2.74e-05	0.000244	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CASP8—atopic dermatitis	2.74e-05	0.000244	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CASP8—atopic dermatitis	2.74e-05	0.000244	CbGpPWpGaD
Bortezomib—Headache—Prednisone—atopic dermatitis	2.73e-05	8.93e-05	CcSEcCtD
Bortezomib—PSMA1—Immune System—IL2—atopic dermatitis	2.73e-05	0.000243	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IL1B—atopic dermatitis	2.73e-05	0.000243	CbGpPWpGaD
Bortezomib—PSMD1—Disease—CD4—atopic dermatitis	2.73e-05	0.000243	CbGpPWpGaD
Bortezomib—PSMD2—Dexamethasone—Prednisolone—atopic dermatitis	2.73e-05	0.00325	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Prednisolone—atopic dermatitis	2.73e-05	0.00325	CbGdCrCtD
Bortezomib—PSMD1—Immune System—IL2—atopic dermatitis	2.72e-05	0.000242	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IL1B—atopic dermatitis	2.72e-05	0.000242	CbGpPWpGaD
Bortezomib—PSMD2—Disease—CD4—atopic dermatitis	2.72e-05	0.000242	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IL2—atopic dermatitis	2.71e-05	0.000241	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CASP8—atopic dermatitis	2.7e-05	0.00024	CbGpPWpGaD
Bortezomib—PSMB8—Norethindrone—Hydrocortisone—atopic dermatitis	2.66e-05	0.00317	CbGdCrCtD
Bortezomib—PSMB1—Metabolism—PPARA—atopic dermatitis	2.66e-05	0.000236	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PPARA—atopic dermatitis	2.66e-05	0.000236	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PPARA—atopic dermatitis	2.66e-05	0.000236	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ADSL—atopic dermatitis	2.65e-05	0.000236	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PPARA—atopic dermatitis	2.62e-05	0.000233	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—NFKBIA—atopic dermatitis	2.59e-05	0.000231	CbGpPWpGaD
Bortezomib—Nausea—Prednisone—atopic dermatitis	2.59e-05	8.46e-05	CcSEcCtD
Bortezomib—PSMD1—Signaling Pathways—NFKBIA—atopic dermatitis	2.58e-05	0.00023	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCL5—atopic dermatitis	2.57e-05	0.000229	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCL5—atopic dermatitis	2.57e-05	0.000229	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCL5—atopic dermatitis	2.57e-05	0.000229	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NFKBIA—atopic dermatitis	2.57e-05	0.000228	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCL5—atopic dermatitis	2.54e-05	0.000226	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—MAPK8—atopic dermatitis	2.51e-05	0.000224	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—MAPK8—atopic dermatitis	2.5e-05	0.000223	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—MAPK8—atopic dermatitis	2.49e-05	0.000222	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GLB1—atopic dermatitis	2.47e-05	0.00022	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NGF—atopic dermatitis	2.38e-05	0.000212	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NGF—atopic dermatitis	2.38e-05	0.000212	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NGF—atopic dermatitis	2.38e-05	0.000212	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ADSL—atopic dermatitis	2.37e-05	0.000211	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NGF—atopic dermatitis	2.35e-05	0.000209	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IFNG—atopic dermatitis	2.33e-05	0.000207	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IFNG—atopic dermatitis	2.33e-05	0.000207	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IFNG—atopic dermatitis	2.33e-05	0.000207	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCR5—atopic dermatitis	2.32e-05	0.000206	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCR5—atopic dermatitis	2.32e-05	0.000206	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCR5—atopic dermatitis	2.32e-05	0.000206	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IFNG—atopic dermatitis	2.3e-05	0.000204	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCR5—atopic dermatitis	2.28e-05	0.000203	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GLB1—atopic dermatitis	2.27e-05	0.000202	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD4—atopic dermatitis	2.25e-05	0.0002	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD4—atopic dermatitis	2.25e-05	0.0002	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD4—atopic dermatitis	2.25e-05	0.0002	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GLB1—atopic dermatitis	2.25e-05	0.0002	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CD4—atopic dermatitis	2.22e-05	0.000197	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	2.2e-05	0.000196	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ADSL—atopic dermatitis	2.18e-05	0.000194	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ADSL—atopic dermatitis	2.16e-05	0.000192	CbGpPWpGaD
Bortezomib—PSMB8—Levonorgestrel—Hydrocortisone—atopic dermatitis	2.11e-05	0.00252	CbGdCrCtD
Bortezomib—PSMB1—Immune System—IL1B—atopic dermatitis	2.08e-05	0.000185	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL1B—atopic dermatitis	2.08e-05	0.000185	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL1B—atopic dermatitis	2.08e-05	0.000185	CbGpPWpGaD
Bortezomib—PSMB2—Disease—CD4—atopic dermatitis	2.08e-05	0.000185	CbGpPWpGaD
Bortezomib—PSMB5—Disease—CD4—atopic dermatitis	2.08e-05	0.000185	CbGpPWpGaD
Bortezomib—PSMB1—Disease—CD4—atopic dermatitis	2.08e-05	0.000185	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL2—atopic dermatitis	2.07e-05	0.000184	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL2—atopic dermatitis	2.07e-05	0.000184	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL2—atopic dermatitis	2.07e-05	0.000184	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL1B—atopic dermatitis	2.05e-05	0.000182	CbGpPWpGaD
Bortezomib—PSMB8—Disease—CD4—atopic dermatitis	2.05e-05	0.000182	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL2—atopic dermatitis	2.04e-05	0.000182	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	2.01e-05	0.000179	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NFKBIA—atopic dermatitis	1.96e-05	0.000175	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NFKBIA—atopic dermatitis	1.96e-05	0.000175	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NFKBIA—atopic dermatitis	1.96e-05	0.000175	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NFKBIA—atopic dermatitis	1.94e-05	0.000172	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GLB1—atopic dermatitis	1.92e-05	0.000171	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—MAPK8—atopic dermatitis	1.91e-05	0.00017	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—MAPK8—atopic dermatitis	1.91e-05	0.00017	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—MAPK8—atopic dermatitis	1.91e-05	0.00017	CbGpPWpGaD
Bortezomib—PSMB8—Dexamethasone—Hydrocortisone—atopic dermatitis	1.88e-05	0.00225	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Hydrocortisone—atopic dermatitis	1.88e-05	0.00225	CbGdCrCtD
Bortezomib—PSMB8—Immune System—MAPK8—atopic dermatitis	1.88e-05	0.000167	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CXCL8—atopic dermatitis	1.85e-05	0.000165	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ADSL—atopic dermatitis	1.84e-05	0.000164	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CXCL8—atopic dermatitis	1.84e-05	0.000164	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CXCL8—atopic dermatitis	1.83e-05	0.000163	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.8e-05	0.00016	CbGpPWpGaD
Bortezomib—PSMB8—Dexamethasone—Methylprednisolone—atopic dermatitis	1.78e-05	0.00212	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Methylprednisolone—atopic dermatitis	1.78e-05	0.00212	CbGdCrCtD
Bortezomib—PSMA1—Signaling Pathways—IL2—atopic dermatitis	1.77e-05	0.000157	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL2—atopic dermatitis	1.76e-05	0.000156	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL2—atopic dermatitis	1.75e-05	0.000156	CbGpPWpGaD
Bortezomib—PSMB8—Betamethasone—Dexamethasone—atopic dermatitis	1.75e-05	0.00209	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Betamethasone—atopic dermatitis	1.75e-05	0.00209	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Triamcinolone—atopic dermatitis	1.71e-05	0.00204	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Triamcinolone—atopic dermatitis	1.71e-05	0.00204	CbGdCrCtD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.64e-05	0.000146	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MAPK8—atopic dermatitis	1.63e-05	0.000145	CbGpPWpGaD
Bortezomib—PSMB8—Dexamethasone—Prednisone—atopic dermatitis	1.62e-05	0.00193	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Prednisone—atopic dermatitis	1.62e-05	0.00193	CbGdCrCtD
Bortezomib—PSMD1—Signaling Pathways—MAPK8—atopic dermatitis	1.62e-05	0.000144	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MAPK8—atopic dermatitis	1.61e-05	0.000143	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—IL6—atopic dermatitis	1.61e-05	0.000143	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IL6—atopic dermatitis	1.6e-05	0.000142	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IL6—atopic dermatitis	1.59e-05	0.000142	CbGpPWpGaD
Bortezomib—PSMB8—Dexamethasone—Prednisolone—atopic dermatitis	1.58e-05	0.00189	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Prednisolone—atopic dermatitis	1.58e-05	0.00189	CbGdCrCtD
Bortezomib—CYP3A4—Metabolism—GLB1—atopic dermatitis	1.48e-05	0.000132	CbGpPWpGaD
Bortezomib—PSMA1—Disease—IL6—atopic dermatitis	1.48e-05	0.000132	CbGpPWpGaD
Bortezomib—PSMD1—Disease—IL6—atopic dermatitis	1.48e-05	0.000131	CbGpPWpGaD
Bortezomib—PSMD2—Disease—IL6—atopic dermatitis	1.47e-05	0.000131	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ADSL—atopic dermatitis	1.42e-05	0.000127	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.4e-05	0.000125	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CXCL8—atopic dermatitis	1.4e-05	0.000125	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CXCL8—atopic dermatitis	1.4e-05	0.000125	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CXCL8—atopic dermatitis	1.4e-05	0.000125	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PPARA—atopic dermatitis	1.39e-05	0.000124	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CXCL8—atopic dermatitis	1.38e-05	0.000123	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL2—atopic dermatitis	1.34e-05	0.000119	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL2—atopic dermatitis	1.34e-05	0.000119	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL2—atopic dermatitis	1.34e-05	0.000119	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL2—atopic dermatitis	1.32e-05	0.000117	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK8—atopic dermatitis	1.23e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK8—atopic dermatitis	1.23e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK8—atopic dermatitis	1.23e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL6—atopic dermatitis	1.22e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL6—atopic dermatitis	1.22e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL6—atopic dermatitis	1.22e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK8—atopic dermatitis	1.21e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL6—atopic dermatitis	1.2e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB2—Disease—IL6—atopic dermatitis	1.12e-05	0.0001	CbGpPWpGaD
Bortezomib—PSMB5—Disease—IL6—atopic dermatitis	1.12e-05	0.0001	CbGpPWpGaD
Bortezomib—PSMB1—Disease—IL6—atopic dermatitis	1.12e-05	0.0001	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—atopic dermatitis	1.11e-05	9.86e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—atopic dermatitis	1.04e-05	9.24e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—atopic dermatitis	1.03e-05	9.2e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—atopic dermatitis	1.03e-05	9.15e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARA—atopic dermatitis	9.78e-06	8.71e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARA—atopic dermatitis	8.97e-06	7.98e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARA—atopic dermatitis	8.01e-06	7.13e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—atopic dermatitis	7.87e-06	7e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—atopic dermatitis	7.87e-06	7e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—atopic dermatitis	7.87e-06	7e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—atopic dermatitis	7.76e-06	6.9e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARA—atopic dermatitis	7.36e-06	6.55e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARA—atopic dermatitis	7.3e-06	6.5e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARA—atopic dermatitis	6.24e-06	5.55e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARA—atopic dermatitis	4.81e-06	4.29e-05	CbGpPWpGaD
